---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-279041"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:38:47.199413+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA imposes clinical hold on Inhibikase's IkT-148009 Parkinson's and MSA programs

## Summary
- FDA placed a clinical hold on the IkT-148009 201 program in Parkinson's disease and its use in Multiple Systems Atrophy (MSA).
- Inhibikase states no serious adverse events have been observed in the ongoing 201 trial to date.
- Official clinical hold letter expected within 30 days; company is actively working with FDA to resolve concerns.
- IkT-148009 is a protein kinase inhibitor for neurodegenerative diseases; no timeline for hold resolution given.

## SEC filing metadata
- accession: 0001193125-22-279041
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312522279041/0001193125-22-279041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312522279041/d377532d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-279041
- JSON: https://secwatch.observer/filing/0001193125-22-279041.json
- Plain text: https://secwatch.observer/filing/0001193125-22-279041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.